Asset profile
Abatacept · Orencia
Protein / enzyme therapeutic
Evidence outlook
Approved: Rheumatoid Arthritis, Psoriatic Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
93 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 93 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Abatacept (Orencia): this drug | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), CD80/CD86 (B7-1/B7-2) on antigen-presenting cells, Selective T Cell Costimulation Modulator | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha | ||
| Adalimumab-Aqvh (Yusimry) | Approved | — | TNF-alpha | ||
| Adalimumab-Atto (Amjevita) | Approved | — | TNF-alpha | ||
| Adalimumab-Bwwd (Hadlima) | Approved | — | TNF-alpha | ||
| Adalimumab-Fkjp (Hulio) | Approved | — | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 |
…and 78 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(21 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
November 2026 (1)
What to watch
December 2026 (1)
What to watch
2027 (10)
January 2027 (1)
What to watch
March 2027 (2)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (2)
What to watch
What to watch
December 2027 (1)
What to watch
2028 (4)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (1)
What to watch
2029 (3)
April 2029 (1)
What to watch
May 2029 (1)
What to watch
December 2029 (1)
What to watch
2032 (1)
June 2032 (1)
What to watch
2034 (1)
September 2034 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.